NME Goal Dates Sparse In Late 2007: Third Year Of Low NME Count Likely
Executive Summary
Only three NDAs for new molecular entities have user fee goal dates in the remainder of 2007, which implies a marked slow-down in the pace of NME actions after FDA's busy October (see chart: "1Remaining Candidates For The NME Class Of 2007")
You may also be interested in...
FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.